The proposed Apollo clinical substrate
Programmable Bio does not currently have contracted access to Apollo Hospitals data, EHR systems, biospecimens, or patients. We intend to pursue a formal collaboration, subject to agreement, consent, ethics review, governance, and applicable law.
The strategic rationale is straightforward: autonomous lab execution becomes more valuable when biological designs can eventually be evaluated against well-governed, population-relevant samples and clinical context. Apollo and its Sapien Biosciences biobank demonstrate the scale of that opportunity, but access would require a separate negotiated program.
What a future collaboration could enable
- Ethics-approved validation using consented, fit-for-purpose biospecimens
- Population-aware assay development and biomarker evaluation
- Federated or controlled analysis where raw clinical data remains within approved infrastructure
- Jointly governed research programs with explicit publication, IP, and commercial terms
Proposed collaboration structure →
Status, principles, governance, and fallback paths.
Future India Biomarker Atlas →
A proposed data product, not a currently available database.
Competitive landscape →
How clinical-context access would complement, not replace, lab execution.
Public context: Apollo company overview and Apollo's 2025 annual/excellence materials. Figures should be reverified before external circulation.